These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 9284371)
1. Resistance, remission, and qualitative differences in HIV chemotherapy. Kirschner DE; Webb GF Emerg Infect Dis; 1997; 3(3):273-83. PubMed ID: 9284371 [TBL] [Abstract][Full Text] [Related]
2. Emergence of HIV-1 drug resistance during antiretroviral treatment. Rong L; Feng Z; Perelson AS Bull Math Biol; 2007 Aug; 69(6):2027-60. PubMed ID: 17450401 [TBL] [Abstract][Full Text] [Related]
3. Understanding drug resistance for monotherapy treatment of HIV infection. Kirschner DE; Webb GF Bull Math Biol; 1997 Jul; 59(4):763-85. PubMed ID: 9214852 [TBL] [Abstract][Full Text] [Related]
4. Mutation and control of the human immunodeficiency virus. Stengel RF Math Biosci; 2008 Jun; 213(2):93-102. PubMed ID: 18439629 [TBL] [Abstract][Full Text] [Related]
5. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124 [TBL] [Abstract][Full Text] [Related]
6. Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects. Smith RJ; Wahl LM Bull Math Biol; 2005 Jul; 67(4):783-813. PubMed ID: 15893553 [TBL] [Abstract][Full Text] [Related]
7. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. Deeks SG; Wrin T; Liegler T; Hoh R; Hayden M; Barbour JD; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK; Grant RM N Engl J Med; 2001 Feb; 344(7):472-80. PubMed ID: 11172188 [TBL] [Abstract][Full Text] [Related]
8. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)]. Panel de expertos de GESIDA y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714 [TBL] [Abstract][Full Text] [Related]
9. Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype. Izopet J; Souyris C; Sandres-Sauné K; Puissant B; Obadia M; Pasquier C; Puel J; Blancher A; Massip P J Med Virol; 2002 Nov; 68(3):305-10. PubMed ID: 12226815 [TBL] [Abstract][Full Text] [Related]
10. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. Wein LM; D'Amato RM; Perelson AS J Theor Biol; 1998 May; 192(1):81-98. PubMed ID: 9628841 [TBL] [Abstract][Full Text] [Related]
11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
12. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. Hance AJ; Lemiale V; Izopet J; Lecossier D; Joly V; Massip P; Mammano F; Descamps D; Brun-Vézinet F; Clavel F J Virol; 2001 Jul; 75(14):6410-7. PubMed ID: 11413308 [TBL] [Abstract][Full Text] [Related]
13. Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection. de Mendoza C; Martín-Carbonero L; Gallego O; Corral A; González-Lahoz J; Soriano V J Med Virol; 2005 May; 76(1):1-6. PubMed ID: 15778973 [TBL] [Abstract][Full Text] [Related]